1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Malaria Infection: new trials by email Literature Review of Malaria Infection trials Research Report on Malaria Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 192 | 2023-11-28 | 2026-02-06 |
Asymptomatic Infections (1) · Malaria (1) · Malaria, Falciparum (1)
Asymptomatic Diseases (1) · Disease Attributes (1) · Infections (1) · Mosquito-Borne Diseases (1) · Parasitic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Protozoan Infections (1) · Vector Borne Diseases (1)
atovaquone, proguanil drug combination (1) · pyronaridine (1)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)
Burkina Faso (1) · Kenya (1) · The Gambia (1) · Zambia (1)